Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct Mechanisms
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Adoptive cell transfer (ACT) of ex vivo–activated autologous tumor-reactive T cells is currently one of the most promising approaches for cancer immunotherapy. Recent studies provided some evidence that IL-17–producing CD8+ (Tc17) cells may exhibit potent antitumor activity, but the specific mechanisms have not been completely defined. In this study, we used a murine melanoma lung-metastasis model and tested the therapeutic effects of gp100-specific polarized type I CD8+ cytotoxic T (Tc1) or Tc17 cells combined with autologous bone marrow transplantation after total body irradiation. Bone marrow transplantation combined with ACT of antitumor (gp100-specific) Tc17 cells significantly suppressed the growth of established melanoma, whereas Tc1 cells induced long-term tumor regression. After ACT, Tc1 cells maintained their phenotype to produce IFN-γ, but not IL-17. However, although Tc17 cells largely preserved their ability to produce IL-17, a subset secreted IFN-γ or both IFN-γ and IL-17, indicating the plasticity of Tc17 cells in vivo. Furthermore, after ACT, the Tc17 cells had a long-lived effector T cell phenotype (CD127hi/KLRG-1low) as compared with Tc1 cells. Mechanistically, Tc1 cells mediated antitumor immunity primarily through the direct effect of IFN-γ on tumor cells. In contrast, despite the fact that some Tc17 cells also secreted IFN-γ, Tc17-mediated antitumor immunity was independent of the direct effects of IFN-γ on the tumor. Nevertheless, IFN-γ played a critical role by creating a microenvironment that promoted Tc17-mediated antitumor activity. Taken together, these studies demonstrate that both Tc1 and Tc17 cells can mediate effective antitumor immunity through distinct effector mechanisms, but Tc1 cells are superior to Tc17 cells in mediating tumor regression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Barth, R. J., Mulé, J. J., Spiess, P. J., & Rosenberg, S. A. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.647 · Cited by 402
Cited by
Heterogeneity in the Differentiation and Function of CD8+ T Cells
Mittrücker, H.-W., Visekruna, A., & Huber, M. (2014) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-014-0293-y · Cited by 325
CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
Chatterjee, S., Daenthanasanmak, A., Chakraborty, P., Wyatt, M. W., Dhar, P., Selvam, S. P., Fu, J., Zhang, J., Nguyen, H., Kang, I., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2017.10.006 · Cited by 270
Self-citationLu, Y., Hong, B., Li, H., Zheng, Y., Zhang, M., Wang, S., Qian, J., & Yi, Q. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1317431111 · Cited by 146
IL-17A-producing T cells are associated with the progression of lung adenocarcinoma
Bao, Z., Lu, G., Cui, D., Yao, Y., Yang, G., & Zhou, J. (2016) · Oncology Reports · doi:10.3892/or.2016.4837 · Cited by 30
Metadata
- Authors
- Yu, Y., Cho, H.-I., Wang, D., Kaosaard, K., Anasetti, C., Celis, E., & Yu, X.-Z.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-02
- Volume
- 190
- Issue
- 4
- Pages
- 1873-1881
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2119313330
- Cited by
- 68
- References
- 1
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct Mechanisms. https://app.cochat.ai/papers/10.4049/jimmunol.1201989
- The paper
- Yu, Y., Cho, H.-I., Wang, D., Kaosaard, K., Anasetti, C., Celis, E., & Yu, X.-Z. (2013). Adoptive Transfer of Tc1 or Tc17 Cells Elicits Antitumor Immunity against Established Melanoma through Distinct Mechanisms. The Journal of Immunology. https://doi.org/10.4049/jimmunol.1201989
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.